Acts as inhibitor of neural Wiskott-Aldrich syndrome protein (N-WASP) by stabilizing the autoinhibited state of the protein. It inhibits actin assembly stimulated by phosphatidylinositol 4,5-bisphosphate (pip2), but does not directly inhibit actin
CAT No: R0915
CAS No: 380488-27-7
Synonyms/Alias: 187-1, N-WASP inhibitor;380488-27-7;CHEMBL436918;Cyclo(L-glutaminyl-L-lysyl-D-phenylalanyl-D-prolyl-D-phenylalanyl-L-phenylalanyl-D-prolyl-L-glutaminyl-L-lysyl-D-phenylalanyl-D-prolyl-D-phenylalanyl-L-phenylalanyl-D-prolyl);3-[(3S,6R,9R,15R,18S,21S,24R,30S,33R,36R,42R,45S,48S,51R)-18,45-bis(4-aminobutyl)-48-(3-amino-3-oxopropyl)-3,6,15,30,33,42-hexabenzyl-2,5,8,14,17,20,23,29,32,35,41,44,47,50-tetradecaoxo-1,4,7,13,16,19,22,28,31,34,40,43,46,49-tetradecazapentacyclo[49.3.0.09,13.024,28.036,40]tetrapentacontan-21-yl]propanamide;QKFPFFPQKFPFFP;BDBM50175058;AKOS024456924;PD079245;G13303;cyclo[L-Lys-D-Phe-D-Pro-D-Phe-L-Phe-D-Pro-L-Gln]2;S-380488-27-7;
Quick InquiryCustom Peptide SynthesisPeptide Library Construction and Screening
Powerful screening tools in biological and chemical research
M.F/Formula | C96H122N18O16 |
M.W/Mr. | 1784.1 |
Sequence | Three Letter Code:cyclo[Gln-Lys-D-Phe-D-Pro-D-Phe-Phe-D-Pro-Gln-Lys-D-Phe-D-Pro-D-Phe-Phe-D-Pro] |
Labeling Target | Neural wiskott-aldrich syndrome protein (N-WASP) |
Appearance | White lyophilised solid |
Purity | >98% |
Activity | Inhibitor |
Solubility | -20 °C |
InChI | InChI=1S/C96H122N18O16/c97-49-21-19-39-67-83(117)107-73(57-63-31-11-3-12-32-63)93(127)113-53-25-43-79(113)91(125)105-71(55-61-27-7-1-8-28-61)87(121)109-75(59-65-35-15-5-16-36-65)95(129)111-51-23-41-77(111)89(123)103-69(45-47-81(99)115)85(119)102-68(40-20-22-50-98)84(118)108-74(58-64-33-13-4-14-34-64)94(128)114-54-26-44-80(114)92(126)106-72(56-62-29-9-2-10-30-62)88(122)110-76(60-66-37-17-6-18-38-66)96(130)112-52-24-42-78(112)90(124)104-70(86(120)101-67)46-48-82(100)116/h1-18,27-38,67-80H,19-26,39-60,97-98H2,(H2,99,115)(H2,100,116)(H,101,120)(H,102,119)(H,103,123)(H,104,124)(H,105,125)(H,106,126)(H,107,117)(H,108,118)(H,109,121)(H,110,122)/t67-,68-,69-,70-,71+,72+,73+,74+,75-,76-,77+,78+,79+,80+/m0/s1 |
InChI Key | PHTIQAVQWWOKNF-RNEDXEELSA-N |
Isomeric SMILES | C1C[C@@H]2C(=O)N[C@@H](C(=O)N[C@H](C(=O)N3CCC[C@@H]3C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N4CCC[C@@H]4C(=O)N[C@@H](C(=O)N[C@H](C(=O)N5CCC[C@@H]5C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N2C1)CC6=CC=CC=C6)CCCCN)CCC(=O)N)CC7=CC=CC=C7)CC8=CC=CC=C8)CC9=CC=CC=C9)CCCCN)CCC(=O)N)CC1=CC=CC=C1)CC1=CC=CC=C1 |
BoilingPoint | N/A |
Melting Point | N/A |
3. Adipose tissue is a key organ for the beneficial effects of GLP-2 metabolic function
5. Cell-based adhesion assays for isolation of snake venom’s integrin antagonists
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at info@creative-peptides.com. We will endeavor to provide highly satisfying products and services.